XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.24.3

Note 13 - Segment Information | 9 Months Ended
--- | ---
Sep. 28, 2024
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | 13. Segment Information The Company follows ASC 280, “Segment Reporting,” which establishes standards for companies to report information about operating segments, geographic areas and major customers. The accounting policies of each reportable segment are the same as those described in the summary of significant accounting policies (see Note 1 to the Company’s Consolidated Financial Statements included in its Annual Report on Form 10-K for the year ended December 30, 2023). Segment operating income includes selling, general and administrative expenses directly attributable to that segment as well as charges for allocating corporate costs to each of the operating segments. The following tables reflect the results of the reportable segments consistent with the Company’s management system:
Thirteen Weeks Ended September 28, 2024 |  | Specialty Health Care |  |  | Engineering |  |  | Life Sciences and IT |  |  | Corporate |  |  | Total |
Revenue |  | $ | 26,554 |  |  | $ | 24,167 |  |  | $ | 9,644 |  |  | $ | - |  |  | $ | 60,365 |
Cost of services |  |  | 18,271 |  |  |  | 18,273 |  |  |  | 5,980 |  |  |  | - |  |  |  | 42,524 |
Gross profit |  |  | 8,283 |  |  |  | 5,894 |  |  |  | 3,664 |  |  |  | - |  |  |  | 17,841 |
Selling, general and administrative |  |  | 6,510 |  |  |  | 4,294 |  |  |  | 2,214 |  |  |  | - |  |  |  | 13,018 |
Depreciation and amortization of property and equipment |  |  | 139 |  |  |  | 200 |  |  |  | 54 |  |  |  | - |  |  |  | 393 |
Amortization of acquired intangible assets |  |  | - |  |  |  | - |  |  |  | 45 |  |  |  | - |  |  |  | 45 |
Operating income |  | $ | 1,634 |  |  | $ | 1,400 |  |  | $ | 1,351 |  |  | $ | - |  |  | $ | 4,385 |
Total assets as of September 28, 2024 |  | $ | 40,525 |  |  | $ | 52,321 |  |  | $ | 21,681 |  |  | $ | 11,018 |  |  | $ | 125,545 |
Property and equipment acquired |  | $ | 68 |  |  | $ | 378 |  |  | $ | - |  |  | $ | 76 |  |  | $ | 522 |
Thirteen Weeks Ended September 30, 2023 |  | Specialty Health Care |  |  | Engineering |  |  | Life Sciences and IT |  |  | Corporate |  |  | Total |
Revenue |  | $ | 24,895 |  |  | $ | 22,452 |  |  | $ | 10,702 |  |  | $ | - |  |  | $ | 58,049 |
Cost of services |  |  | 17,438 |  |  |  | 16,846 |  |  |  | 6,484 |  |  |  | - |  |  |  | 40,768 |
Gross profit |  |  | 7,457 |  |  |  | 5,606 |  |  |  | 4,218 |  |  |  | - |  |  |  | 17,281 |
Selling, general and administrative |  |  | 5,977 |  |  |  | 4,327 |  |  |  | 2,358 |  |  |  | - |  |  |  | 12,662 |
Depreciation and amortization of property and equipment |  |  | 88 |  |  |  | 122 |  |  |  | 33 |  |  |  | - |  |  |  | 243 |
Amortization of acquired intangible assets |  |  | - |  |  |  | - |  |  |  | 45 |  |  |  | - |  |  |  | 45 |
Operating income |  | $ | 1,392 |  |  | $ | 1,157 |  |  | $ | 1,782 |  |  | $ | - |  |  | $ | 4,331 |
Total assets as of September 30, 2023 |  | $ | 32,272 |  |  | $ | 45,949 |  |  | $ | 17,662 |  |  | $ | 5,331 |  |  | $ | 101,214 |
Property and equipment acquired |  | $ | 62 |  |  | $ | 162 |  |  | $ | 69 |  |  | $ | 22 |  |  | $ | 315 |
Thirty-Nine Weeks Ended September 28, 2024 |  | Specialty Health Care |  |  | Engineering |  |  | Life Sciences and IT |  |  | Corporate |  |  | Total |
Revenue |  | $ | 101,668 |  |  | $ | 70,180 |  |  | $ | 29,620 |  |  | $ | - |  |  | $ | 201,468 |
Cost of services |  |  | 71,672 |  |  |  | 52,818 |  |  |  | 18,769 |  |  |  | - |  |  |  | 143,259 |
Gross profit |  |  | 29,996 |  |  |  | 17,362 |  |  |  | 10,851 |  |  |  | - |  |  |  | 58,209 |
Selling, general and administrative |  |  | 21,252 |  |  |  | 12,515 |  |  |  | 6,995 |  |  |  | - |  |  |  | 40,762 |
Depreciation and amortization of property and equipment |  |  | 372 |  |  |  | 505 |  |  |  | 135 |  |  |  | - |  |  |  | 1,012 |
Amortization of acquired intangible assets |  |  | - |  |  |  | - |  |  |  | 136 |  |  |  | - |  |  |  | 136 |
Costs associated with potential stock issuance |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 259 |  |  |  | 259 |
Operating income (loss) |  | $ | 8,372 |  |  | $ | 4,342 |  |  | $ | 3,585 |  |  | $ | (259 | ) |  | $ | 16,040 |
Total assets as of September 28, 2024 |  | $ | 40,525 |  |  | $ | 52,321 |  |  | $ | 21,681 |  |  | $ | 11,018 |  |  | $ | 125,545 |
Property and equipment acquired |  |  | 235 |  |  | $ | 622 |  |  | $ | 20 |  |  | $ | 712 |  |  | $ | 1,589 |
Thirty-Nine Weeks Ended September 30, 2023 |  | Specialty Health Care |  |  | Engineering |  |  | Life Sciences and IT |  |  | Corporate |  |  | Total |
Revenue |  | $ | 99,553 |  |  | $ | 61,956 |  |  | $ | 30,700 |  |  | $ | - |  |  | $ | 192,209 |
Cost of services |  |  | 70,623 |  |  |  | 47,482 |  |  |  | 19,039 |  |  |  | - |  |  |  | 137,144 |
Gross profit |  |  | 28,930 |  |  |  | 14,474 |  |  |  | 11,661 |  |  |  | - |  |  |  | 55,065 |
Selling, general and administrative |  |  | 19,211 |  |  |  | 12,626 |  |  |  | 6,945 |  |  |  | - |  |  |  | 38,782 |
Depreciation and amortization of property and equipment |  |  | 281 |  |  |  | 370 |  |  |  | 105 |  |  |  | - |  |  |  | 756 |
Amortization of acquired intangible assets |  |  | - |  |  |  | - |  |  |  | 136 |  |  |  | - |  |  |  | 136 |
Gain on sale of assets |  |  | - |  |  |  | (395 | ) |  |  | - |  |  |  | - |  |  |  | (395 | )
Operating income |  | $ | 9,438 |  |  | $ | 1,873 |  |  | $ | 4,475 |  |  | $ | - |  |  | $ | 15,786 |
Total assets as of September 30, 2023 |  | $ | 32,272 |  |  | $ | 45,949 |  |  | $ | 17,662 |  |  | $ | 5,331 |  |  | $ | 101,214 |
Property and equipment acquired |  | $ | 109 |  |  | $ | 640 |  |  | $ | 88 |  |  | $ | 38 |  |  | $ | 875 |
The Company derives a majority of its revenue from offices in the United States. Revenues reported for each operating segment are all from external customers. The Company is domiciled in the United States and its segments operate in the United States, Canada, Puerto Rico and Europe. Revenue by geographic area for the thirteen and thirty-nine weeks ended September 28, 2024 and September 30, 2023 was as follows:
|  | Thirteen Weeks Ended |  |  | Thirty-Nine Weeks Ended |
|  | September 28, 2024 |  |  | September 30, 2023 |  |  | September 28, 2024 |  |  | September 30, 2023 |
Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
United States |  | $ | 55,322 |  |  | $ | 53,679 |  |  | $ | 185,742 |  |  | $ | 179,800 |
Canada |  |  | 1,895 |  |  |  | 1,647 |  |  |  | 4,982 |  |  |  | 5,060 |
Puerto Rico |  |  | 1,568 |  |  |  | 1,643 |  |  |  | 5,588 |  |  |  | 4,745 |
Europe |  |  | 1,580 |  |  |  | 1,080 |  |  |  | 5,156 |  |  |  | 2,604 |
|  | $ | 60,365 |  |  | $ | 58,049 |  |  | $ | 201,468 |  |  | $ | 192,209 |
Total assets by geographic area as of the reported periods were as follows:
|  | September 28, 2024 |  |  | December 30, 2023 |
Total assets |  |  |  |  |  |  |  |
United States |  | $ | 114,067 |  |  | $ | 110,781 |
Canada |  |  | 1,924 |  |  |  | 1,880 |
Puerto Rico |  |  | 3,127 |  |  |  | 3,476 |
Europe |  |  | 6,427 |  |  |  | 4,347 |
|  | $ | 125,545 |  |  | $ | 120,484 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration